News and Trends 19 Sep 2022 Bugworks Research and Cytecare Cancer Hospitals to set up cancer research center Bugworks Research Inc., a clinical stage biopharmaceutical company, and Cytecare Cancer Hospitals are set to collaborate by setting up a dedicated research center. Suresh Ramu, co-founder & CEO, Cytecare Cancer Hospitals, said: “We are excited to partner with Bugworks Research, in this inspiring endeavor to discover novel treatments for different types of cancers. In 2016, […] September 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 16 Sep 2022 Strategic collaboration for drug to treat NASH, obesity and diabetes announced A conditional and exclusive license agreement to develop and commercialize a drug to treat nonalcoholic steatohepatitis (NASH), obesity and type 2 diabetes has been agreed. NeuroBo Pharmaceuticals and Dong-A ST Co., announced their strategic collaboration today (September 16) for DA-1241 and DA-1726 which are currently being evaluated for treatment. DA-1241 is a novel G-Protein-Coupled Receptor […] September 16, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Sep 2022 Ghana first to benefit from Roche partnership with Jhpiego to improve cervical and breast cancer outcomes for women Roche has signed a memorandum of understanding (MoU) with the Johns Hopkins Program for International Education in Gynecology and Obstetrics (Jhpiego) to improve cervical and breast cancer outcomes in resource-constrained countries. Breast cancer is the most diagnosed cancer and the cause of the most cancer-related deaths in women. Similarly, cervical cancer is the fourth most […] September 16, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Sep 2022 Neuron23 and QIAGEN to collaborate on diagnostic for novel Parkinson’s drug Neuron23 Inc. and QIAGEN are to collaborate to develop a companion diagnostic for Neuron23’s LRRK2 inhibitor for Parkinson’s disease. Under the agreement, QIAGEN will develop and validate a clinical trial assay that will detect a combination of biomarkers discovered by Neuron23 that together predict the responsiveness of Parkinson’s disease patients to a LRRK2 inhibitor. The […] September 15, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2022 Collaboration to explore gene therapy products for neurodegenerative disorders Coave Therapeutics is collaborating with the Institute of Neurodegenerative Diseases (IMN) of Bordeaux to develop gene therapy proteins targeting protein degradation in neurodegenerative disorders. The IMN is a joint research unit associating the University of Bordeaux and the French National Centre of Scientific Research (CNRS) developing gene therapy programs targeting protein degradation in neurodegenerative disorders. […] September 14, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2022 Astellas, Seagen and Merck give details on urothelial cancer treatment Astellas Pharma Inc., Seagen Inc. and Merck (known as MSD outside of the U.S. and Canada), have announced results from the phase 1b/2 EV-103 clinical trial (KEYNOTE-869) Cohort K investigating PADCEV (enfortumab vedotin-ejfv) in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) and PADCEV alone as first-line treatment in patients with unresectable locally advanced or metastatic […] September 12, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 CRISPR/CAS9 strategic alliance between Sigma-Aldrich and genOway expanded Sigma-Aldrich Co LLC, along with genOway, a preclinical research model space company, announced today (September 8) they have a new structure to their 2018 strategic alliance in the CRISPR/Cas9 field. In 2018, science and technology company Merck, of which Sigma-Aldrich is a subsidiary, announced a strategic alliance in the CRISPR/Cas9 rodent model market with France-based […] September 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 OncoBone signs deals with three partners to work on bone metastases OncoBone Ventures has signed cooperation framework agreements with three partners. The company is a U.K. start up biotech looking to develop novel therapies for cancer patients with currently incurable bone metastases. The partners are: Okayama University in Japan, the University of Bradford in the U.K., and The Development Center for Biotechnology in Taiwan. The agreements […] September 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2022 Lonza and Touchlight collaboration will expands customer’s access to DNA Manufacturing partner, Lonza, has today (September 6) announced a collaboration with Touchlight, a biotech company that works with enzymatic DNA production enabling genetic medicine. Through this collaboration, Lonza says it will have the ability to expand it end-to-end offering for mRNA manufacturing with an additional source of DNA raw material. This material comes from Touchlight’s […] September 6, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2022 Synaffix and Emergence in $360M technology platform deal to develop ADCs Dutch biotech Synaffix B.V. and German Emergence Therapeutics announced today (September 6) they have entered into a licensing agreement of up to $360 million. The agreement will provide Emergence access on a target-specific basis to Synaffix’s antibody drug conjugate (ADC) technologies made up of Glycoconnect, HydraSpace and SYNtecan E linker payload. Under the terms of […] September 6, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2022 CellOrigin Biotech and Qilu Pharmaceutical to develop CAR-iMAC cell therapy CellOrigin Biotech (Hangzhou) Co., Ltd. and Qilu Pharmaceutical are to collaborate on strategic global collaborations to develop, manufacture and commercialize ‘off-the-shelf’ induced pluripotent stem cells (iPSC)-derived chimeric antigen receptor macrophages (CAR-iMAC) for cancer immunotherapy. Both companies will work on new drug development and commercialization, and will push CAR-iMAC pipelines forward to clinical trials. “Innovation, and […] September 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2022 Synairgen to collaborate on study of patients hospitalized due to respiratory viruses Synairgen plc is to collaborate on a University of Southampton study on acute respiratory viral infection and recovery in hospital patients. The UNIVERSAL (Understanding Infection, Viral Exacerbation and Respiratory Symptoms at Admission-Longitudinal) trial is an observational study being led by the Clinical Trials Unit of the University of Southampton in the U.K. to explore and […] September 5, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email